Tagraxofusp: First Global Approval

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

(2018) Rajeswaran Mani et al.   HAEMATOLOGICA

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

(2018) Weili Sun et al.   Journal of Hematology & Oncology

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34 + CD123 + cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

(2018) Rajeswaran Mani et al.   HAEMATOLOGICA

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells

(2017) A Ray et al.   LEUKEMIA

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

(2014) F. Angelot-Delettre et al.   HAEMATOLOGICA

A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia

(2010) Hyun Pyo Kim et al.   LEUKEMIA RESEARCH

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA